Bringing Clinical Trials to Life

Dermatology

Together, Cu-Tech and Synteract create the leading dermatology CRO, with global capabilities and unparalleled access to sites and patients. Our focus on novel and required dermatology drugs provides dedicated research services unmatched in the market.
More...

Oncology

Like our clients, we are committed to the quest to cure cancer. But cancer is not just a single disease. It takes deep trial knowledge to know how to address its many forms. Learn how Synteract has stayed ahead of the trends leading towards new treatments…
More...

Neuro Degenerative

Neuro degenerative disorders are some of the most confounding and complex to affect people. Our specialized experience in these trials aids you in developing treatments that improve functioning and help the lives of both patients and caregivers…
More...

Rare & Orphan Diseases

Rare and orphan diseases have unique characteristics, not the least of which is finding the right population for your trials. We know the investigators and study sites that can help to address your recruitment goals, among other challenges…
More...

Pediatrics

Pediatric trials run the gamut of indications in drug development, but they all have primary things in common – working with children and their families requires specialized expertise and deep knowledge of regulatory requirements….
More...

10/19/2018 - 10/23/2018 : EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY More...

9/25/2018: Synteract welcomes Lisa Dilworth who joins as vice president, rare and orphan diseases, and Elisabeth Schrader as executive director, program strategy, pediatrics and rare diseases. More ...

8/24/2018: Get to Know Francoise Desir – Our 2018 PharmaVOICE 100 Recipient - We sat down with Francoise Desir, Senior Project Manager, to find out her thoughts about being named a PharmaVOICE 100 recipient, learn more about her experience with Synteract, and get to know her personally.

Synteract Blog 

10/20/2018: We are ready for the weekend. How about you? Here are 16 things you should do at the end of every workday: http://ow.ly/mTnH50jrfJU

Synteract on LinkedIn

10/18/2018: Dr. Martine Dehlinger-Kremer, VP of Pediatric Development, provides her insights on the current state of #pediatric… https://t.co/3S31HlqXr3

Synteract Twitter Feed
x

Contact Synteract

Tell us how to stay in touch with you:

*Required